Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Biomarkers) of BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg qd for 10 Days. A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Trial With Open-label Active Comparator
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 653048 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Aug 2014 New trial record